AstraZeneca closed a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to create Dizal Pharmaceutical in China. The equally-owned, stand-alone company aims to discover, develop and commercialise potential new medicines to help meet unmet needs globally, and to bring innovative new medicines to patients in China faster. Dizal Pharmaceutical will incorporate all scientific and technical capabilities of AstraZeneca’s Innovation Center China (ICC), and holds exclusive rights to develop and commercialise three potential medicines currently in pre-clinical development from AstraZeneca’s pipeline.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here